Recordati Industria Chimica e Farmaceutica ... It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold ...

The active ingredient of Eligard® is leuprorelin acetate, a powder which is solubilized with a solvent for subcutaneous injection. Eligard® is available in three different dosages (for 1-month ...

Another promising product Recordati acquires in the deal is Caphosol, an FDA-approved medical device to counter some side effects from chemotherapy and radiotherapy. Also included is Sylvant ...

as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria ...

MILAN, Nov 26 (Reuters) - The main shareholder of Italy's Recordati (RECI.MI), opens new tab is in contact with other Italian drugmakers over a possible sale, the chief executive of rival Dompe ...

Recordati will acquire global rights to Enjaymo for $825M upfront and up to $250M in milestone payments. Enjaymo generated €100M in revenue in 2024 and is expected to exceed €150M in 2025 ...

Angelini and Recordati have been discussing the possibility of a deal that would create a larger European generic drugmaker, said the people, who asked not to be identified as the information is ...

MILAN, Jan 17 (Reuters) - Recordati (RECI.MI), opens new tab and its top shareholder CVC Capital Partners on Friday denied any plans to combine the Italian drugmaker with smaller rival Angelini ...

The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM ...